Roche's Actemra wins new RA indication; Allergan fails to save Sanctura XR patent;

@FiercePharma: Profile of one man who's shaking up India's patent-protected drugmakers: Cipla founder YK Hamied. More | Follow @FiercePharma

> Roche's ($RHHBY) arthritis drug Actemra won FDA approval for a new indication in adults with moderate to severe disease who've failed on disease-modifying antirheumatic drugs such as methotrexate. Report

> Allergan ($AGN) failed to convince the Supreme Court to weigh its patent on the bladder drug Sanctura XR, which was invalidated by a U.S. appeals court in June, clearing the way for Watson Pharmaceuticals ($WPI) to launch its generic version. News | Report

> The Irish government and the pharma industry came to a deal on drug prices, which includes a big, two-step cut in generics prices and a one-time cut in branded drug prices. Report

> Onyx Pharmaceuticals ($ONXX) wrapped up enrollment for a Phase 3 trial of Kyprolis, which will test the drug as monotherapy in multiple myeloma patients whose treatment with three other therapies has failed. Release

> Teva Pharmaceuticals Industries ($TEVA) opened its new, $110 million in Hungary, which will supply 70 countries in Europe, North America and Asian. Report

> Shanghai Fosun Pharmaceutical plans to launch its Hong Kong stock offering Tuesday, aiming to raise up to $600 million. Report

Biotech News

 @FierceBiotech: How should India regulate its clinical trial industry? More | Follow @FierceBiotech

 @JohnCFierce: Zounds! Sloan-Kettering won't use Zaltrap (Sanofi/Regeneron) based on its cost and efficacy. Influential. More | Follow @JohnCFierce

 @RyanMFierce: New website crowdsources cancer therapies (some ideas more useful than others). More | Follow @RyanMFierce

> Aegerion shares surge on FDA review of rare cholesterol disease drug. Report

> Merck hooks late-stage infectious-disease portfolio with $571M deal. Article

> AstraZeneca turns to Beijing CRO as it scrambles to repair damaged pipeline. News

Medical Device News

 @FierceMedDev: Heart stent surgeries in China are now second only to the U.S., but more than half may be unnecessary. More | Follow @FierceMedDev

 @MarkHFierce: BSX CEO explains its repositioning is an attempt, in part, to respond to a rapidly changing healthcare industry. More | Follow @MarkHFierce

 @DamianFierce: Will GSK's new transparency pledge be a boon for CROs and drug developers? More | Follow @DamianFierce

> Medtronic, St. Jude Medical pursue diversity as MN mulls same-sex marriage ban. Item

> BD, Lab21 team up for cancer diagnostics. Story

Biotech IT News

> Australia goes online for clinical trials awareness. Report

> Fight against 'unwarranted' drug patents goes online. More

> GSK to open clinical data vaults to scientists via website. Story

> Pharma group taps software to track adverse events in mobile apps. Article

CRO News

> How should India regulate its clinical trial industry? Item

> AstraZeneca taps China's Pharmaron to speed R&D. Report

> GSK's transparency pledge could be a boon to drug researchers. News

> Recipharm teams with Astimex on CDMO deal. Story

> Novasep pours $39M into new API plant. Article

And Finally... Children with ADHD said that their drug treatment helps them control their behavior, a study found. More

Suggested Articles

Late-stage ovarian cancer patients have few options, but now the FDA is reviewing GSK's Zejula for the patient group.

The FDA has raised questions about the manufacturing of Glenmark's new molecular entity Ryaltris, a nasal spray for seasonal allergic rhinitis.

Despite unconventional support from President Donald Trump, Johnson & Johnson’s Spravato didn’t win broad backing at the VA.